BofA raised the firm’s price target on Alnylam (ALNY) to $359 from $336 and keeps a Buy rating on the shares. BofA conducted a survey with 25 cardiologists treating 3,150 ATTR-CM patients to better understand initial dynamics of the Amvuttra launch, with respondents indicating they have written 195 scripts since the launch with a ~50/50 split for newly diagnosed and switch patients, the analyst tells investors in a research note. Respondents expect Amvuttra could have ~29% share at peak and expect it to reach ~25% share over the next 24 months, BofA adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $404 from $364 at Citi
- Alnylam Pharma’s Promising Growth and Market Potential Justify Buy Rating
- Alnylam price target raised to $384 from $328 at Jefferies
- Alnylam announces reimbursement of OXLUMO in Canada
- Strong Sales Momentum and Growth Potential Drive Buy Rating for Alnylam Pharma’s Amvuttra